Aegerion Pharmaceuticals: Recordati to commercialise Aegerion Pharma's rare genetic disease drug Juxtapid in Japan
Novelion Therapeutics Inc, a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that its subsidiary, Aegerion
Read full article »
CEO
Aegerion is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of severe and rare diseases.
Read more